PROCESS OF MAKING RACEMIC BUPIVACAINE'S ENANTIOMERS, LEVOBUPIVACAINE'S PHARMACEUTICAL COMPOSITIONS, LEVOBUPIVACAINE'S PHARMACEUTICAL COMPOSITIONS FORMULATED ON ITS FREE BASE FORM OR ITS PHARMACEUTICAL ACCEPTABLE SALTS AND USE OF LEVOBUPIVACAINE'S PHARMACEUTICAL COMPOSITIONS FORMULATED ON ITS FREE BASE FORM

摘要

The prevent invention describes a new method for the separation of bupivacaine enantiomers consisting in a continous separation process performed without heating, by the selective precipitation of their diastereomeric salts with tartaric acid. This heatless process avoids the degradation of the reagents granting a continuous process feature to the procedure. Another embodiment of the present invention is related to the enantiomeric manipulation of bupivacaine enantiomers in order to obtain pharmaceutical compositions presenting several enantiomeric excess of levobupivacaine to quantify and determinate the role of the dextrobupivacaine on its anesthetic and cardiotoxic effects. These enantiomeric manipulated compositions showed to present an expressive improvement on its anesthetic properties that has shown to be similar to racemic bupivacaine presenting a cardiotoxic profile similar to enantiomeric pure levobupivacaine.